Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPHY U-01: Sacituzumab Govitecan in Metastatic Urothelial Cancer
NCT03547973Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2018
- Primary completion
- Apr 2030
- Countries
- 9
01
Overview
A Phase 2 trial of sacituzumab govitecan in urothelial carcinoma (UC), sponsored by Gilead Sciences. Started Aug 2018; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03547973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547973.